Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins and continues exploring oral formulations. The evaluation agreement was extended precisely to the October 7, 2026 resolution date, leaving roughly seven weeks for a formal commercial license to materialize without prior signals. These factors underpin the 87.5% market-implied probability on “No,” reflecting limited progress and competing priorities in Lilly’s long-acting peptide strategy.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% chance
$11,264 Vol.
$11,264 Vol.
7 out 2026
13% chance
$11,264 Vol.
$11,264 Vol.
7 out 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins and continues exploring oral formulations. The evaluation agreement was extended precisely to the October 7, 2026 resolution date, leaving roughly seven weeks for a formal commercial license to materialize without prior signals. These factors underpin the 87.5% market-implied probability on “No,” reflecting limited progress and competing priorities in Lilly’s long-acting peptide strategy.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado Aberto: May 5, 2026, 8:02 PM ET
Volume
$11,264Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins and continues exploring oral formulations. The evaluation agreement was extended precisely to the October 7, 2026 resolution date, leaving roughly seven weeks for a formal commercial license to materialize without prior signals. These factors underpin the 87.5% market-implied probability on “No,” reflecting limited progress and competing priorities in Lilly’s long-acting peptide strategy.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins and continues exploring oral formulations. The evaluation agreement was extended precisely to the October 7, 2026 resolution date, leaving roughly seven weeks for a formal commercial license to materialize without prior signals. These factors underpin the 87.5% market-implied probability on “No,” reflecting limited progress and competing priorities in Lilly’s long-acting peptide strategy.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions